# Wilfred Jaeger

> Wilfred Jaeger is a Series C investor at Three Arch Partners backing Health Care. See 14 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Three Arch Partners](https://shizune.co/investors/profile/three-arch-partners)
- Location: San Mateo, United States
- Total investments: 14
- Last investment: Jun 2017
- Lead investor: 14%
- Last updated: Aug 2026

Wilfred Jaeger is a Series C investor at Three Arch Partners in San Mateo focused on Health Care and Biotechnology. Prior to co-founding Three Arch Partners, Wilfred was a general partner at Schroder Ventures. Wilfred began his medical career in private practice. He was subsequently recruited by Chec Medical, a venture capital backed ambulatory care startup in Seattle. Later, in 1989, following business school, he began venture investing with PhoenixPartners. He has since been an active early stage investor in numerous successful biotechnology, healthcare service, and medical device companies. He has served on the boards of many private and public healthcare companies.Wilf ranked first in his class at the University of British Columbia where he earned a BS in Biology. He received his MD from the University of British Columbia School of Medicine. He has an MBA from the Stanford Graduate School of Business.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 36% |
| Biotechnology | 4 | 29% |
| Medical Device | 3 | 21% |
| Health Diagnostics | 2 | 14% |
| Medical | 1 | 7% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 3 | 21% |
| Series A | 2 | 14% |
| Series B | 2 | 14% |
| Seed | 1 | 7% |
| Series D | 1 | 7% |

9 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Neuronetics | Neuronetics is focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. They are the first and only company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment. | $15M | Series G | Jun 06, 2017 |  |
| Neuronetics | Neuronetics is focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. They are the first and only company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment. | $34.3M | Series F | Apr 27, 2015 |  |
| Nevro | Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza systemis the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro. |  | Series C | Mar 07, 2013 |  |
| Access Closure | Access Closure, Inc., a medical device company, provides access site management products to address the complex challenge of vascular closure during interventional and diagnostic procedures. The company's products include Mynx delivery system, a vascular closure device that seals the arteriotomy using a water-soluble and extravascular sealant,which expands in the tissue tract by absorbing blood and subcutaneous fluids. Access Closure, Inc. was founded in 2002 and is based in Mountain View, California. | $998.1K |  | Oct 01, 2012 |  |
| Access Closure | Access Closure, Inc., a medical device company, provides access site management products to address the complex challenge of vascular closure during interventional and diagnostic procedures. The company's products include Mynx delivery system, a vascular closure device that seals the arteriotomy using a water-soluble and extravascular sealant,which expands in the tissue tract by absorbing blood and subcutaneous fluids. Access Closure, Inc. was founded in 2002 and is based in Mountain View, California. | $2.8M |  | Jan 01, 2012 |  |
| Nevro | Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza systemis the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro. |  | Series B | Jul 19, 2011 |  |
| Neuronetics | Neuronetics is focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. They are the first and only company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment. |  | Series E | May 16, 2011 |  |
| Neuronetics | Neuronetics is focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. They are the first and only company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment. | $30M | Series D | Oct 27, 2009 |  |
| Nevro | Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza systemis the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro. | $21.8M | Series A | Sep 10, 2008 |  |
| Concert Pharmaceuticals | Concert Pharmaceuticals is a clinical-stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium.Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline ofnew chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with the potential for efficacy and safety, while greatly reducing R&D risk, time, and expense. | $37M | Series C | Apr 30, 2008 |  |

10 of 14 investments shown.

## Co-investors
- [New Leaf Venture Partners](https://shizune.co/investors/profile/new-leaf-venture-partners) — VC Fund, 6 deals together
- [ONSET Ventures](https://shizune.co/investors/profile/onset-ventures) — VC Fund, 5 deals together
- [Bay City Capital](https://shizune.co/investors/profile/bay-city-capital) — VC Fund, 4 deals together
- [Mayo Clinic](https://shizune.co/investors/profile/mayoclinic) — VC Fund, 4 deals together
- [Aberdare Ventures](https://shizune.co/investors/profile/aberdare-ventures) — VC Fund, 3 deals together
- [Greylock](https://shizune.co/investors/profile/greylock) — VC Fund, 3 deals together

## About Three Arch Partners

VC Fund · Portola Valley, United States

Three Arch Partners was formed in 1993 to provide young companies with access to relevant clinical and business resources, as well as capital. Three Arch has helped create, build and fund more than 100 important new healthcare companies. These companies have often become the clinical and market leaders in their respective fields, and have generatedstrong returns. The fund focuses on opportunities in medical devices and healthcare services, and less frequently in biotechnology.

5 contacts available at Three Arch Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Wilfred Jaeger | Co - Founder & Partner | https://shizune.co/investors/profile/wilfred-jaeger |
| Barclay Nicholson | Administrative Partner | https://shizune.co/investors/profile/barclay-nicholson |
| Mark Wan | Managing Director | https://shizune.co/investors/profile/mark-wan |
| Richard Lin | Partner | https://shizune.co/investors/profile/richard-lin |
| Rod Young | Venture Partner | https://shizune.co/investors/profile/rod-young |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Wilfred Jaeger invest in?

Wilfred Jaeger invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series C and Series A stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Wilfred Jaeger last invest?

The most recent investment recorded for Wilfred Jaeger closed in Jun 2017. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co